Small cell lung cancer (SCLC)
GPTKB entity
Properties (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
lung cancer
|
| gptkbp:advertising |
gptkb:Lung_Cancer_Awareness_Month
gptkb:World_Lung_Cancer_Day |
| gptkbp:aftermath |
rare
|
| gptkbp:associatedWith |
smoking
thrombosis paraneoplastic syndromes |
| gptkbp:barrelLength |
low
|
| gptkbp:careInstructions |
initially responsive to chemotherapy
|
| gptkbp:characterizedBy |
small cells
|
| gptkbp:clinicalTrials |
Phase IV
Phase II Phase III ongoing research rapid growth Phase I ASCO guidelines resistance to treatment early metastasis NCCN_guidelines |
| gptkbp:commonName |
bone
brain liver |
| gptkbp:demographics |
more common in men
typically diagnosed in older adults |
| gptkbp:diseaseResistance |
biopsy
poor imaging tests high recurrence rate limited surgical options |
| gptkbp:geneticDiversity |
TP53
RB1 |
| https://www.w3.org/2000/01/rdf-schema#label |
Small cell lung cancer (SCLC)
|
| gptkbp:impact |
surgery
radiation therapy chemotherapy targeted therapy |
| gptkbp:number_of_stages |
extensive stage
limited stage |
| gptkbp:relatedPatent |
lungs
mediastinum |
| gptkbp:research |
gptkb:NCI
NIH |
| gptkbp:researchFocus |
biomarkers
immunotherapy |
| gptkbp:riskManagement |
family history
exposure to asbestos |
| gptkbp:safetyFeatures |
smoking cessation
screening for high-risk individuals |
| gptkbp:series |
common
|
| gptkbp:structureType |
neuroendocrine cells
|
| gptkbp:symptoms |
weight loss
cough chest pain |
| gptkbp:type |
neoplasm
|